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Over the last several decades, basic cardiovascular research has significantly enhanced our understanding of pathobiological processes leading
to formation, progression, and complications of atherosclerotic plaques. By harnessing these advances in cardiovascular biology, imaging has
advanced beyond its traditional anatomical domains to a tool that permits probing of particular molecular structures to image cellular behav-
iour and metabolic pathways involved in atherosclerosis. From the nascent atherosclerotic plaque to the death of inflammatory cells, several
potential molecular and micro-anatomical targets for imaging with particular selective imaging probes and with a variety of imaging modalities
have emerged from preclinical and animal investigations. Yet, substantive barriers stand between experimental use and wide clinical application
of these novel imaging strategies. Each of the imaging modalities described herein faces hurdles—for example, sensitivity, resolution, radiation
exposure, reproducibility, availability, standardization, or costs. This review summarizes the published literature reporting on functional
imaging of vascular inflammation in atherosclerotic plaques emphasizing those techniques that have the greatest and/or most immediate po-
tential for broad application in clinical practice. The prospective evaluation of these techniques and standardization of protocols by multi-
national networks could serve to determine their added value in clinical practice and guide their development and deployment.
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Introduction
Atherosclerosis affects the arterial tree in a continuum. The
disease may take root early in life, but it does not become clinically
overt until atherosclerotic plaques reach a critical stage. Certain
clinical manifestations of the disease relate to the impairment of
tissue perfusion due to luminal encroachment by the growing
plaque, causing impaired blood flow and symptoms such as
angina pectoris. Such plaques generally have a fibrotic morphology,
often referred to in shorthand as ‘stable’ lesions. Patients with this
type of lesion have quite a low mortality rate (≤3% annually).
Imaging has established utility in the non-invasive diagnosis of
such flow-limiting atherosclerotic lesions, informing risk stratifica-
tion and allocation to an appropriate management strategy.
The development and refinement of non-invasive cardiac
imaging over the past two decades has provided new tools for
the identification of preclinical disease that reach beyond identifica-
tion of flow-limiting stenoses. Studies using positron emission tom-
ography (PET) for the non-invasive quantification of regional
myocardial blood flow (mL/min/g) have demonstrated dysfunction
of the coronary microvasculature (arterioles ,300 mm of diam-
eter) in asymptomatic subjects with a normal angiogram who
have risk factors for CAD—such as hypercholesterolaemia, essen-
tial hypertension, diabetes mellitus, and smoking.1,2 These studies
have provided evidence of how cardiovascular risk factors alter
coronary microvascular function, in the absence of stenoses of
the epicardial coronary arteries. Such microvascular dysfunction
without epicardial stenosis can also produce chest discomfort, a
scenario that applies particularly to women.
Atherosclerosis may, however, assume another preclinical form
associated with potentially devastating effects: the development of
often non-obstructive, but ‘unstable’ arterial plaques that may
rupture and provoke acute thrombosis, causing unheralded
events such as acute myocardial infarction and stroke.3,4 As ana-
tomical imaging has matured over the last several decades, our
unravelling of the cellular and molecular mechanisms of cardiovas-
cular disease has expanded markedly. Research has identified
several molecular targets, biochemical pathways, and cellular
* Corresponding author. Tel: +39 0226436202, Fax: +39 0226436218, Email: camici.paolo@hsr.it
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2012. For permissions please email: journals.permissions@oup.com
European Heart Journal (2012) 33, 1309–1317
doi:10.1093/eurheartj/ehs067
markers that furnish expanding insight into the mechanisms of car-
diovascular diseases.5 These advances offer an enormous oppor-
tunity to expand imaging beyond the traditional anatomical and
physiological domains, by harnessing these advances in basic car-
diovascular biology to image particular molecular structures, cellu-
lar behaviours, and metabolic pathways, and probe the biological
processes that underlie cardiovascular diseases.
Table 1 summarizes the armamentarium of non-invasive imaging
techniques available for molecular imaging. Nuclear techniques,
such as PET and single-photon emission computed tomography
(SPECT), stand out because of their high sensitivity for small
amounts of probe mass, but these modalities have relatively
limited spatial resolution. In contrast, magnetic resonance imaging
(MRI) and computed tomography (CT) have superior spatial reso-
lution, but less sensitivity. Optical techniques, such as biolumines-
cence or fluorescence imaging, have restricted tissue penetration
depth, presenting challenges to imaging deep arteries in large
animals and humans. Experimental investigations have used these
techniques in conjunction with a variety of molecular-targeted
compounds, but few have made their way into the clinic.6–8
While many previous reports have focused on the pathobiological
features of plaque vulnerability, we shall concentrate here on those
compounds and non-invasive modalities that have the greatest po-
tential for rapid application to clinical practice.9
Pathobiology and targets for
non-invasive imaging
Early in the formation of atherosclerotic lesions, the endothelial
cells that form the interface of the arterial wall with the circulation
focally change their palette of homoeostatic functions and adopt an
altered molecular programme. These changes, crucial for host
defences following tissue injury or infection, can prove deleterious
in the context of atheroma formation. The normal arterial endo-
thelial monolayer tonically exhibits anticoagulant, pro-fibrinolytic,
vasodilator, antioxidant, and anti-inflammatory properties. When
endothelial cells sense danger—as signalled by bacterial products
such as endotoxin, or by molecules associated with cardiovascular
risk factors such as constituents of modified low-density lipopro-
tein, angiotensin II, or pro-inflammatory cytokines—the homoeo-
static panel of properties gives way to a predominance of
pro-coagulant and anti-fibrinolytic mediators, to impairment of
the vasodilator function, and often to generation of vasoconstrict-
or substances, as well as a gamut of pro-inflammatory functions.
Among these changes, the expression of adhesion molecules on
the surface of the activated endothelial cells can capture blood leu-
cocytes. Of these endothelial-leucocyte adhesion molecules, vas-
cular cell adhesion molecule-1 (VCAM-1) has received
considerable attention as a target for molecular imaging
(Figure 1).10,11 Other adhesion molecules that mediate the attach-
ment of monocytes and T cells include the fractalkine receptor
CX3CR1. In established atherosclerotic lesions, plexi of microves-
sels can provide a large surface area of endothelial cells that furnish
an apt target for imaging (Figure 1). Current approaches to imaging
such adhesion molecules include microbubbles linked with anti-
bodies that recognize the adhesion molecules selectively and
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permit visualization by contrast-enhanced ultrasound (CEU).
Approaches to improve the stoichiometry of the targeting
moiety to the imaging moiety of an agent include the use of pep-
tides identified by screening of phage-display libraries. Peptide-
linked imaging agents that can target VCAM-1 include those
coupled to near infrared fluorophores, and radionuclides.12 The
neovessels within the plaque arise by angiogenesis and often
bear integrins, such as anb3, that have also served as targets for
imaging agents.13,14
The most predominant leucocyte recruited to the artery wall
during atherogenesis, the blood monocyte, matures into a macro-
phage once resident in the arterial intima (Figure 1). Tissue macro-
phages can become phagocytically active, a process very important
in internalizing pathogens during host defence reactions. In the
context of atherosclerosis, internalization of lipoprotein particles
yields foam-cell formation. This phagocytic capacity furnishes further
opportunity for imaging of a cellular process. Nanoparticles that
undergo phagocytosis can provide a target for imaging of inflammatory
cells. Ultra-small particulate iron oxide particles (USPIOs), rendered
biocompatible with tunable kinetics in the circulatory system due
to coating with dextran molecules of various chain lengths,
generate an MRI signal when engulfed by plaque macrophages.15
Early in the response to hyperlipidaemia, lipoproteins accumu-
late in the intima. Sequestered from plasma antioxidants, lipids
and lipoproteins that accumulate in the arterial intima undergo oxi-
dative modification that provides another potential target for mo-
lecular imaging. Epitopes associated with oxidized phospholipids
generate antibodies that, when linked to radionuclides, can
report on the accumulation of modified lipoproteins in
atherosclerotic lesions.16 Lipid accumulation and the formation
of modified lipids furnish other opportunities for imaging—for
example, by near infrared or Raman spectroscopy.
Mononuclear phagocytes within the plaque may change their
metabolic activity when undergoing inflammatory activation. As
glucose uptake enjoys wide use in tumour imaging, many groups
have documented increased uptake of the positron-labelled
glucose analogue 18F-fluorodeoxyglucose (FDG) in atheromata
using PET. Thus, increased uptake of FDG may provide a marker
for metabolically active inflammatory cells in plaques that could
prove clinically useful, given the widespread use of this approach
in oncology and availability of the tracer (see below).
Once recruited and resident in the arterial intima, mononuclear
phagocytes amplify and perpetuate the local inflammatory processes
by producing mediators that can contribute to the progression and
complication of atherosclerotic plaques. Activated phagocytes can
produce elevated levels of reactive oxygen species. Plaque macro-
phages can express myeloperoxidase, an enzyme that produces
hypochlorous acid (HOCl), a highly pro-oxidant species. Molecular
imaging techniques can visualize myeloperoxidase and its
product.17,18 Smooth-muscle cells and phagocytes within the
plaque express NADPH oxidases that generate superoxide anions.
Thus reporters of reactive oxygen species could provide another ap-
proach to imaging inflammation within plaques.
Considerable work has substantiated the overproduction by
plaque macrophages of enzymes that catabolize constituents of
the arterial extracellular matrix.19 Breakdown of collagen and
elastin, the major constituents of the arterial extracellular matrix,
can prove pivotal in arterial remodelling and in weakening of the
Figure 1 Imaging targets in the atherosclerotic plaque. The diagram on the left depicts a plaque in the carotid bifurcation. The exploded view
in the middle illustrates the composition of the plaque (lumen to the right), showing a calcified region in blue at the base of the plaque on the
left, macrophages in the lipid rich necrotic core (yellow), triple helical collagen fibrils, and smooth-muscle cells in the plaque’s fibrous cap
(brown) underlying the endothelial monolayer. The blue dots represent spotty calcification. The microvessels also penetrate the base of
the plaque from the adventitia. Various imaging targets on the major cell types shown are listed on the right. MMPs, matrix metalloproteinases;
VCAM-1, vascular cell adhesion molecule-1.
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collagenous skeleton that renders plaques susceptible to rupture
and, hence, to thrombosis. In response to inflammatory mediators,
virtually all cell types within atherosclerotic plaques can over-
express proteases capable of extracellular matrix degradation.
The key enzymes in collagen breakdown, the interstitial collage-
nases, belong to the matrix metalloproteinase (MMP) family. Acti-
vated mononuclear phagocytes within plaques also overproduce
elastolytic sulfhydryl proteinases such as cathepsins S, K, and L,
all implicated in arterial remodelling in atherosclerosis by experi-
mental studies. Serine proteinases, including neutrophil elastase,
also may participate in arterial remodelling during atherogenesis.
Several approaches can visualize such proteinases. Protease inhibi-
tors conjugated with radionuclides constitute one approach to
visualizing MMPs. Proteolytic cleavage of quenched fluorescence
substrates makes use of the catalytic potential of these enzymes.
While inhibitors bind in a one-to-one stoichiometry to the pro-
teases, a single enzyme molecule can cleave many substrate mole-
cules using catalysis to amplify the fluorescent signal. Although
animal experiments have validated the utility of both approaches,
extension to humans requires further work.20–22 Notably, the de-
velopment of intra-vascular probes that can detect near infrared
fluorescent signals can provide a platform for translation of these
optical approaches to humans, albeit invasively.23
Advanced human atherosclerotic plaques contain zones of fibro-
sis. Accumulation of gadolinium, detectable by MRI, may allow visu-
alization of plaque fibrosis, vascularity, or permeability using
existing imaging agents and platforms.24,25 Calcification within ath-
erosclerotic plaques reflects a dynamic biological process, not
mere mineral accretion, and gives a strong signal on CT. Thus, visu-
alization of calcification, including regions of spotty calcification
that can promote plaque instability, provides another window on
a biological feature of plaques that may reflect inflammatory activa-
tion (Figure 1).26 Although fibrosis and calcification may be targets
for molecular imaging, they may characterize ‘stable’ lesions as well
as those prone to rupture and thrombosis.
Ultimately, mononuclear phagocytes within plaques can die
either by oncosis or by programmed cell death (apoptosis). Cells
undergoing apoptosis characteristically exteriorize phosphatidyl
serine. The protein annexin V, bound to radionuclides, can visualize
apoptotic cells. As apoptosis may occur more frequently in
lipid-rich plaques with ongoing inflammation, markers of this bio-
logical process may also provide a probe into aspects of plaque
biology that relate to their complication.27 Thus, from the
nascent atherosclerotic plaque to the death of inflammatory and
vascular cells, molecular imaging approaches provide an exciting
new window on visualizing biological processes that may contribute
to plaque evolution, and ultimately to thrombotic complication.
Positron emission tomography
The serendipitous observation that some arteries can take up FDG
administered for tumour visualization has spawned much interest
in using this convenient and well-established agent to visualize ath-
erosclerosis.28 The first clinical study of PET-FDG imaging of
human atherosclerosis was published in 2002, and it demonstrated
increased FDG uptake in carotid plaques associated with recent
cerebrovascular ischaemic events.29 When tissue from human
atherosclerotic plaques, obtained following endarterectomy, was
incubated ex vivo with tritiated deoxyglucose, the tracer was
taken up by plaque macrophages, but not by surrounding vascular
smooth-muscle cells or by normal vessels. Subsequent studies have
shown that the uptake of FDG correlates significantly with plaque
macrophage content, and is 20 times higher in the most inflamed
plaques than in control arteries.30,31 The use of PET-FDG imaging
has been extended to other large arteries of the body (aorta,
femoral, and iliac arteries) since then.28,32 The FDG signal in ath-
erosclerotic plaques correlates well with circulating inflammatory
biomarkers,28,33 older age,34 male sex,35 and the presence of trad-
itional cardiovascular risk factors.33,36 Additionally, some studies
have documented a good short-term inter-scan repeatability (2
weeks to 3 months), an important prerequisite for studies using
FDG uptake as a surrogate endpoint for plaque-stabilizing treat-
ments.28,37 Early pilot studies using a high-fat dietary preparation
to prevent spillover artefacts from myocardial FDG uptake have
also demonstrated that coronary and aortic FDG uptake often
associates with symptoms of acute myocardial ischaemia.38,39
These observations led to the conclusion that the FDG signal in
atheromata reports on inflammation. Several groups have shown
that interventions—notably, treatment with HMG-CoA reductase
inhibitors (statins)—can reduce FDG signals.40,41 Effective thera-
peutic intervention to reduce FDG uptake has raised hope that
FDG signals can allow evaluation of novel therapeutics that may
alter inflammation in atherosclerotic plaques. Indeed, several
dozen clinical trials currently underway use FDG uptake as a bio-
marker of inflammation within plaques.
Despite these attractions, some issues require resolution before
embracing FDG uptake in this regard. Firstly, only limited prospect-
ive data correlate FDG uptake, or changes in FDG uptake, with
cardiovascular events or altered rates of such complications,42
and we eagerly await the results of larger prospective cohort
studies, such as the High Risk Plaque Initiative and BioImage
studies.43,44 We lack sufficient validation of the ability of multi-
centre studies to provide standardized data on FDG uptake. Infor-
mation regarding false positives, false negatives, sensitivity, and re-
producibility on longitudinal follow-up remains rudimentary.
Although FDG signals that co-localize with carotid atheromata
present little difficulty with identifying the region of interest, and
show modest background signal, considerable barriers to using
FDG uptake to visualize coronary atheromata exist—because of
avid glucose uptake by myocytes, and substantial myocardial back-
ground even under conditions of high-dietary fat intake to suppress
cardiac myocyte FDG uptake.
In addition, mechanisms other than inflammation may generate
FDG signal associated with atheromata. Microvessels in the
plaque may increase delivery of the radiolabelled glucose analogue,
enriching its local-specific radioactivity in the glucose pool and
giving rise to greater accumulation within cells and signal gener-
ation that may not reflect absolute increases in glucose transport.
Other biological processes, including hypoxia, may drive increased
glucose utilization by mononuclear phagocytes, a putative major
source of the FDG signal in atheromata.45 In particular, studies
of human mononuclear phagocytes have not consistently shown
increased glucose uptake in response to pro-inflammatory media-
tors. In contrast, hypoxia readily stimulates glucose uptake by these
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cells. Hence hypoxia, rather than inflammation, may increase
glucose and hence FDG uptake by inflammatory cells in athero-
mata. In addition, statins can decrease hypoxia-induced augmenta-
tion in glucose uptake in human mononuclear phagocytes in vitro.45
Thus, the attenuation of the FDG signal by statins may not neces-
sarily reflect an anti-inflammatory action. In this regard, nuclear
agents that image hypoxia, already in use in oncology, may be
useful in imaging atherosclerosis, as hypoxic conditions may
prevail in the core of lesions.45
Moreover, some have questioned the specificity of FDG for acti-
vated macrophages. A micro-autoradiography study of aortic sec-
tions of ApoE2/2 mice showed a poor correlation of 14C-FDG
uptake with fat content and selective macrophage staining with
anti-CD68 in atherosclerotic plaques.46 Davies et al.47 reported
that, at variance with ex vivo findings, in vivo FDG micro-PET
uptake in atherosclerotic lesions of rabbit aorta did not correlate
with macrophage accumulation (r ¼ 0.16, P ¼ 0.57), and that
FDG uptake in rabbits with highly inflamed aortic walls, those
with low levels of inflammation, or controls did not differ signifi-
cantly. In summary, although FDG has many attractive aspects
for clinical use in characterizing atheromata, its underlying biologic-
al mechanisms and clinical significance remain incompletely under-
stood and validated. As a result, other compounds have emerged
for interrogating vascular inflammation with PET.
The 11C-labelled PET tracer PK11195 is a selective ligand of the
translocator protein (TSPO, 18 kDa), formerly known as periph-
eral benzodiazepine receptor.48 Translocator proteins were dis-
covered in the 1970s as benzodiazepine-binding sites outside the
central nervous system.49 Subsequent studies have shown a high
TSPO density in circulating human phagocyte populations, particu-
larly in monocytes and neutrophils, with up to 750 000 binding
sites per cell.50 Mature monocytic cell lines have higher TSPO ex-
pression than do pro-monocytic or pro-myelocytic lines. Levels of
TSPO increase two- to three-fold after monocyte activation in vitro
with interferon-gamma or phorbol 12-myristate 13-acetate. Stimu-
lated human monocytes can express .2 000 000 binding sites for
PK11195. This increase accompanies enhanced expression of
CD11a and CD11b surface antigens and increased production of
interleukin-1, interleukin-8, and tumour necrosis factor, indicating
that TSPO over-expression associates with activation of phago-
cytes.51 11C-PK11195 has been used extensively for the non-
invasive imaging of neuroinflammatory and neurodegenerative con-
ditions due to its high uptake in activated microglia and low uptake
in neurons.52 Subsequent studies have demonstrated uptake of
11C-PK11195 by synovial macrophages in patients with rheumatoid
arthritis.53
Fujimura et al.54 showed specific binding of 3H-PK11195 to
macrophages in samples of human carotid atherosclerotic plaque.
In a small proof-of-concept study by Pugliese et al.55 in patients
with large-vessel vasculitis (predominantly giant-cell arteritis and
Takayasu arteritis), 11C-PK11195 PET/CT allowed detection and
quantification of aortic inflammation. Of 15 patients, all 6 patients
with signs and symptoms of active vasculitis (visual disturbance,
headache, bruit or vascular pain/tenderness, new claudication,
fever, night sweats, and/or arthralgia) had markedly increased vas-
cular uptake of 11C-PK11195 [target-to-background ratio (TBR),
2.41], whereas patients with quiescent disease had background
uptake (TBR, 0.98). Standardized uptake values for 11C-PK11195
correlated well with quantitative total intra-plaque volumes of dis-
tribution, calculated from dynamic tissue kinetic modelling using a
1-tissue compartment model.56 In a subsequent study from the
same group, 32 patients with carotid stenoses (of which 9 had
recently suffered an acute cerebrovascular ischaemic event)
underwent 11C-PK11195 PET/CT angiographic (CTA) imaging.57
Carotid plaques associated with ipsilateral symptoms [stroke or
transient ischaemic attack (TIA)] had higher TBR (1.06+ 0.20 vs.
0.86+ 0.11, P ¼ 0.001) and lower CT attenuation [(median, inter-
quartile range) 37, 24–40 vs. 71, 56–125 Hounsfield units, P ¼
0.01] than those without ipsilateral symptoms (Figure 2). Eight
patients underwent carotid endarterectomy, and plaques were
harvested for ex vivo analysis: on immunohistochemistry and con-
focal fluorescence microscopy, CD68 and TSPO co-localized
with 3H-PK11195 uptake at autoradiography. 11C-PK11195 TBR
correlated significantly with percentage specific binding of
3H-PK11195 determined by autoradiography (r ¼ 0.77, P ¼ 0.025).
These preliminary results indicate that ligands of the TSPO hold
promise as molecular-targeted imaging compounds to interrogate
the presence of intra-plaque inflammation in patients with athero-
sclerotic disease, and should encourage further prospective studies
to assess the predictive value of 11C-PK11195 or similar TSPO
ligands for cardiovascular events. Extending 11C-PK11195 PET/
CT imaging to the coronary arteries represents a great challenge
due to the small vessel calibre, the relatively low spatial resolution
of PET, and cardiac and respiratory motion. Nonetheless, a prelim-
inary report of imaging temporal arteritis with 11C-PK11195 PET/
CT demonstrates its feasibility in smaller arteries (with a diameter
of 2 mm).58 Moreover, myocardial uptake of 11C-PK11195
should be lower than for FDG, thus causing less confounding
effects from background signal for imaging coronary arteries. The
short physical half-life (20 min) of 11C-PK11195, which mandates
an on-site cyclotron facility, may limit wide clinical applicability.
But newly introduced 18F-labelled TSPO ligands, currently under-
going preclinical investigation, have shown applicability across
species in the brain and may overcome some of these barriers.59
Computed tomography
Traditionally, CT angiography is an anatomical imaging modality
with limited functional imaging capabilities. Its high temporal and
spatial resolution allow detailed anatomical delineation of large-
and medium-sized vessels and have advanced CT angiography as
the most accurate and robust clinical method for non-invasive cor-
onary angiography. Additionally, co-registration of CT angiograms
with functional techniques such as PET, SPECT, or MRI (in a
hybrid approach) allows the allocation of focal functional signals
to micro-anatomical structures. The high CT attenuation of calci-
fied structures allows a simple qualitative characterization of
plaque composition by dividing coronary lesions into calcified,
non-calcified, and mixed plaques (Figure 3).60 With regard to non-
calcified plaques, however, we lack persuasive evidence suggesting
reliable sub-classification of plaques as lipid-rich vs. fibrous, based
on CT density measurements. Different studies report wide
overlap in Hounsfield units for lipid-rich vs. fibrous plaques.
Reasons for this overlap include the relatively limited spatial
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Figure 3 Qualitative characterization of coronary plaques as non-calcified (A), mixed (B), and calcified (C) by computed tomography angi-
ography. Pixelwise characterization of plaque composition based on CT tissue density (Hounsfield units, HU) (D–F). Blue denotes soft tissue
components with low density (,30 HU, presumably lipid-rich necrotic tissue), pink denotes soft-tissue components with high density
(.30 HU, presumably fibrous tissue), and yellow denotes calcified components (.460 HU). The green area indicates contrast-filled coronary
lumen. The insets show representative cross sections of the coronary artery taken at the site of the arrow. Courtesy of Philipp A. Kaufmann,
Cardiac Imaging, University Hospital Zurich.
Figure 2 Computed tomography angiography (A), [11C]-PK11195 positron emission tomography (B), and positron emission tomography/
computed tomography fusion (C) in a 66-year-old right-handed male patient with a 90% left internal carotid artery stenosis (solid arrows)
who developed a facial droop and dysphasia 3 weeks before the positron emission tomography study. Note focal [11C]-PK11195 uptake
along the convexity of the plaque (B, C, solid arrows). In contrast, images in a 78-year-old asymptomatic female patient with an 80% right
ICA stenosis (D–F). There is no visible [11C]-PK11195 uptake in the region of the plaque (open arrows). The black arrowhead denotes high
[11C]-PK11195 uptake in the submandibular gland, and the asterisk denotes high uptake in bone marrow. Reproduced with permission
from Pugliese et al.55
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resolution of CTA (with subsequent partial volume effects) and a
variable intra-plaque contrast uptake interfering with the native
density of plaque components.61 Finally, CTA cannot yet identify
plaques with thin fibrous caps [so-called thin-cap fibro-atheroma
(TCFA)], as current devices lack the spatial resolution to detect
the thickness of the fibrous cap (65 mm), although some
TCFA may produce a ring-like enhancement on CTA.62
Several other plaque characteristics on CTA associate with
acute ischaemic events. A few small retrospective studies have
consistently shown that culprit lesions of acute coronary syn-
dromes (ACS) had larger vessel areas, more positive remodelling,
and a higher proportion of non-calcified and mixed plaque compo-
nents.63 Hoffmann et al.64 demonstrated a significantly larger
plaque area (17.5 vs. 13.5 mm2) and a higher remodelling index
(1.4 vs. 1.2) in culprit lesions of ACS patients, compared with
patients with stable angina. One retrospective study in 71 patients
showed that culprit lesions in patients with ACS had more positive
remodelling (87 vs. 12%), more low-density (,30 Hounsfield
units) plaque components (79 vs. 9%), and a higher prevalence
of ‘spotty’ calcifications (63 vs. 21%).65 A prospective validation
study confirmed the former two features as significant predictors
of ACS in .1000 patients.66 Pundziute et al.60 observed a higher
prevalence of non-calcified and mixed plaques among culprit
lesions of ACS patients (32 and 59%, respectively), while stable
angina patients more commonly had calcified lesions (61%). IVUS-
defined TCFAs in ACS patients associated most frequently with
lesions classified as mixed on CTA.
Finally, CT has shown promising preliminary results in the
context of molecular imaging of intra-plaque inflammation using
targeted nanoparticle contrast agents. The compound N1177 is a
suspension composed of crystalline iodinated particles dispersed
with surfactant with a high affinity to activated macrophages.67 In
atherosclerotic rabbits, CT density of plaques after N1177 injec-
tion correlated with FDG uptake.68 But despite encouraging find-
ings in animals, some have raised concerns about the low
sensitivity of CT to detect molecular contrast agents.69 Spectral
(or multicolour) CT, which can identify types of tissue based on
their characteristic energy-dependent photon attenuation, may
thereby enhance the sensitivity of CT to detect targeted contrast
agents. In atherosclerotic mice, spectral CT enabled detection of
intra-plaque inflammation after injection of gold-labelled high-
density lipoprotein nanoparticles designed to target activated
macrophages.70 The feasibility and clinical applicability of CT for
molecular imaging of plaque vulnerability awaits clinical translation
to humans.
Magnetic resonance imaging
The combination of multiple MR sequences, either with bright-
blood [time-of-flight (TOF)] or black-blood flow suppression,71,72
can identify the main components of vascular lesions (Figure 1)—
such as the fibrous cap,73 lipid-rich necrotic core (LRNC),74–76
intra-plaque haemorrhage,77–79 neovasculature,80,81 and signs of
vascular wall inflammation.82–85
Emerging evidence links biomechanical forces to the pathogen-
esis of plaque vulnerability,86–89 and to the timing of symptoms.90
Using MRI and finite element analysis to calculate the mechanical
stress within carotid plaques, Sadat et al.90 suggested that the
maximum circumferential stress within the plaques of patients
with acute symptoms exceeds that in plaques of recently symp-
tomatic patients, and that plaques associated with recurrent TIAs
had significantly higher stress than those associated with a single
episode of TIA.91
Extensive MRI studies have validated the characterization of vul-
nerable plaques, including LRNC and the thin fibrous cap, by histo-
logical analysis of retrieved endarterectomy specimens.77,92 At
1.5 T, bright-blood TOF images show the intact fibrous cap as a
continuous hypo-intense band against the bright lumen with a
smooth surface. Discontinuity of the hypo-intense band, juxtalum-
inal hyperintensity in TOF and T1-weighted images (indicating
recent haemorrhage), and an irregular surface characterize
fibrous cap rupture. Mitsumori et al.73 reported 81% sensitivity
and 90% specificity at 1.5 T for identifying a thin, ruptured
fibrous cap. The LRNC has a high content of cholesterol and cho-
lesteryl esters that have short transverse relaxation (T2), resulting
in a hypo-intense signal in T2-weighted images. Using multi-
sequence (T1-weighted, T2-weighted, proton density, and 3D
TOF) imaging, Yuan et al.77 found high sensitivity (85%) and speci-
ficity (92%) for the identification of LRNC.
Fibrous cap rupture detected by MRI associates with symp-
toms93 or cerebrovascular accidents.94 Interestingly, in patients
with mild-to-moderate stenosis, the thin/ruptured fibrous cap
associated significantly with LRNC and symptoms, whereas in
patients with severe stenosis, only the presence of ulceration at
MR angiography associated with symptoms.93 In 138 asymptomatic
patients who had a 50–79% carotid stenosis, those patients whose
plaques were characterized by thinned or ruptured fibrous caps,
large LRNC, intra-plaque haemorrhage (IPH), and large
maximum wall thickness had a higher incidence of cerebrovascular
accidents.95 As stated earlier, activation of mononuclear phago-
cytes promotes the evolution of the atherosclerotic lesion. Two
MRI strategies may delineate macrophage accumulation in the
atheromatous plaque: (i) dynamic kinetics of tissue enhancement
after administration of gadolinium contrast; (ii) USPIOs that
target macrophages in vivo. Enhancement of plaque tissue with
gadolinium contrast may link directly to increased highly permeable
vascular supply within the plaque. The transfer constant (Ktrans) of
gadolinium into the extravascular extracellular space, calculated
from dynamic kinetics of tissue enhancement, correlates strongly
with macrophage content, and to a lesser extent with neovascula-
ture and loose matrix areas measured at histology.96 Interestingly,
Ktrans associates significantly with low HDL levels and smoking, but
not with recent cerebral ischaemic symptoms.
As noted above, activated macrophages infiltrating the plaque
engulf USPIOs rendered biocompatible by coating with materials
such as dextran.84,97 The internalization of the ferromagnetic
USPIOs leads to a change in the resonance frequency of surround-
ing water molecules and a shortening of their relaxation times,
which appears as a signal loss in T2-weighted sequences
(Figure 4). In human plaques, however, the loss of signal also
reflects other features such as a partial volume effect, local haem-
orrhage, and calcification. Several techniques to generate a positive
signal with high signal-to-noise ratio are under investigation.98,99
USPIOs may have slow uptake, requiring long circulating times to
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obtain an adequate accumulation allowing a good signal-to-noise
ratio.100 Notwithstanding these practical and theoretical limita-
tions, the ATHEROMA trial used USPIOs in 40 patients to demon-
strate that aggressive lipid-lowering therapy with atorvastatin over
a 3-month period associated with a significant reduction in plaque
uptake.101
Intra-plaque haemorrhage can originate from rupture of the vasa
vasorum,102 and localize deep in the core of the lesion or occur
from fissures at the luminal surface.103 The degradation of haemo-
globin to methaemoglobin shortens the relaxation (T1) time. As a
consequence, recent haemorrhage appears as a bright signal on
black-blood T1-weighted sequences and magnetization-prepared
rapid acquisition gradient echo (MP-RAGE).104 A few MRI
studies have suggested a role for IPH in plaque destabilization,
and its association with subsequent cerebrovascular
events.78,105,106 More recently, Zhao et al.107 questioned this role
in a study of 181 patients with carotid stenoses .50%. The use
of MR coronary angiography remains predominantly investigational,
and the characterization of coronary artery plaques adds to the
technical challenges. Using T1-weighted black-blood inversion re-
covery before (N-IR) and after administration of gadolinium con-
trast (CE-IR), Maintz et al.108 made an effort to classify the
coronary plaques of CAD patients as hypo-intense on N-IR and
CE-IR (type 1), hyperintense both on N-IR and on CE-IR (type 2),
and hypo-intense on N-IR and hyperintense on CE-IR (type 3).
Contrast uptake may link to both inflammation and fibrosis;
however, the correlation of these features with the progress of
disease remains poorly understood, and awaits confirmation in
larger-scale studies.
Contrast-enhanced
ultrasonography
Targeted microbubbles have undergone experimental evaluation
for visualizing cell surface structures implicated in plaque
rupture.109,110 The compressible gas bubbles produce acoustic
energy by resonating or releasing free gas when insonated. Most
studies involving microbubble-based imaging agents have used anti-
bodies as the targeting moiety. Other targeting strategies have
involved the use of peptides and glycoproteins. Targets successfully
visualized experimentally with contrast-induced ultrasound include
leucocyte adhesion molecules such as intracellular adhesion
molecule-1, VCAM-1, and P-selectin (Figure 1). Antibodies that rec-
ognize glycoprotein IIb/IIIa or peptides that contain the RGD se-
quence have succeeded experimentally in imaging activated
platelets in thrombi. Targeting integrins such as avb3 also may
serve to visualize microvessels. Unlabelled microbubbles can delin-
eate neovascular channels in atherosclerotic plaques or the sur-
rounding adventitia, providing another window on the
characteristics associated with plaques at high risk of rupture.111,112
Figure 4 Automated segmentation of bright- and black-blood, high-spatial-resolution, multi-contrast in vivo magnetic resonance imaging.
Quantification of in vivo magnetic resonance imaging (TOF, T1W, T2W, and CE T1W) using CASCADE to generate component outlines.
The CASCADE fibrous cap is an additional algorithm that collects the fibrous cap length, depth, and area. The automated map of the
plaque is produced by the MEPPS algorithm. The loose matrix is shown in purple, lipid-rich necrotic core in yellow, and intra-plaque haemor-
rhage in red on the MEPPS image. Histology from a carotid endarterectomy sample confirms the components and the enhancing thick fibrous
cap (arrow). In vivo CMR were acquired on a 3T scanner along with the use of an eight-element phased-array carotid coil. CASCADE, computer-
aided system for cardiovascular disease evaluation; CE, contrast-enhanced; CEA, carotid endarterectomy; MEPPS, morphology-enhanced probabil-
istic plaque segmentation; TOF, time-of-flight; T1W, T1-weighted; T2W, T2-weighted. Reproduced with permission from Chu B, Ferguson MS,
Chen H, et al.Magnetic resonance imaging features of the disruption-prone and the disrupted carotid plaque J Am Coll Cardiol Img 2009; 2:883–896.
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Limitations of contrast-enhanced ultrasound include the short
half-life of these bubbles in vivo, their restriction to the intravascular
compartment, and the low contrast-to-noise ratio. Advantages
include the very large installed base of ultrasound apparatuses,
and the familiarity of this modality to practicing clinicians. More-
over, the lack of ionizing radiation also renders this approach at-
tractive for routine clinical use.
Conclusions
Findings from the clinic and the laboratory during the last several
decades have revolutionized our thinking about the mechanisms
of thrombotic complications of atherosclerosis. The traditional
focus on stenosis has given way to the recognition that micro-
anatomical and biological aspects of plaques also influence the pro-
pensity to provoke thrombotic complications. Advances in ana-
tomical imaging open up the prospect of non-invasive
approaches to defining the features of atheromata associated
with clinical complications. Progress in the understanding of the
biological basis of plaque disruption has identified molecular and
cellular targets that extend the scope of imaging beyond
anatomy. The field of imaging of atherosclerosis seems poised at
the threshold of exciting new advances.
Yet, we still need to confront several substantive challenges to
make clinical imaging of the rupture-prone plaque a reality. Each
modality discussed here faces limitations with respect to wide-
spread application to patients, particularly with the goal of identi-
fying plaques with characteristics of instability in the coronary
circulation. Production of some molecular probes requires
access to a cyclotron and radiopharmacy facilities capable of
good manufacturing practices (GMP)-level production. While
often available in specialized centres, the installed base of the infra-
structure for advanced imaging may limit dissemination of its
routine use in patients. Moreover, myocardial background uptake
has presented particular challenges for coronary arterial imaging
with FDG. Radiation exposure and the difficulty of molecular tar-
geting with radio-iodinated contrast agents present barriers to the
clinical application of computed tomographic techniques to identify
so-called vulnerable plaques. On the other hand, while well-
validated sequences and dedicated coils are available for obtaining
images of the carotid arteries and ‘vulnerable’ plaques with MRI,
cardiac and respiratory motion restricts the current effectiveness
of MRI in the coronary tree. New techniques that have proved
promising in animal experiments—including near-infrared detec-
tion of fluorescent probes and contrast-enhanced ultrasound—
likewise have limits with respect to platforms for non-invasive de-
tection of optical signals, and contrast-to-noise ratios in the ultra-
sound arena.
As more groups focus on novel approaches to imaging athero-
sclerosis worldwide, and with appropriate academic–industrial
partnerships and public funding, many of these barriers should
prove superable. Technology-intensive imaging modalities will
likely not prove cost-effective in widespread screening, and will
require careful consideration of indications for routine clinical
use. Nonetheless, practical approaches to the imaging of inflamma-
tion and plaque at high risk of rupture will teach us a great deal
about the human biology of atherosclerotic complications. The
advent of such tools could prove immensely helpful in the develop-
ment and testing of novel therapeutics for atherosclerotic disease,
and could help us confront the unmet medical need of the residual
burden of atherosclerotic events in the face of a growing global
epidemic. Meanwhile, small, prospective, proof-of-principle
studies to evaluate the ability of these new techniques to predict
events in patients at risk of plaque rupture could provide indispens-
able information on their clinical value, and guide future
developments.
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